journal article·2019-12-19Open access

Immunohistochemical Expression of Wilms’ Tumor 1 Protein in Human Tissues: From Ontogenesis to Neoplastic Tissues

Lucia Salvatorelli, Giovanna Calabrese, Rosalba Parenti, Giada Maria Vecchio, Lidia Puzzo, Rosario Caltabiano, Giuseppe Musumeci, Gaetano Magro

Applied Sciences· Volume 10· Issue 1

Abstract

The human Wilms’ tumor gene (WT1) was originally isolated in a Wilms’ tumor of the kidney as a tumor suppressor gene. Numerous isoforms of WT1, by combination of alternative translational start sites, alternative RNA splicing and RNA editing, have been well documented. During human ontogenesis, according to the antibodies used, anti-C or N-terminus WT1 protein, nuclear expression can be frequently obtained in numerous tissues, including metanephric and mesonephric glomeruli, and mesothelial and sub-mesothelial cells, while cytoplasmic staining is usually found in developing smooth and skeletal cells, myocardium, glial cells, neuroblasts, adrenal cortical cells and the endothelial cells of blood vessels. WT1 has been originally described as a tumor suppressor gene in renal Wilms’ tumor, but more recent studies emphasized its potential oncogenic role in several neoplasia with a variable immunostaining pattern that can be exclusively nuclear, cytoplasmic or both, according to the antibodies used (anti-C or N-terminus WT1 protein). With the present review we focus on the immunohistochemical expression of WT1 in some tumors, emphasizing its potential diagnostic role and usefulness in differential diagnosis. In addition, we analyze the WT1 protein expression profile in human embryonal/fetal tissues in order to suggest a possible role in the development of organs and tissues and to establish whether expression in some tumors replicates that observed during the development of tissues from which these tumors arise.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Renal and related cancers · Renal cell carcinoma treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical and Surgical Sciences and Advanced Technologies, G.F. Ingrassia, Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele”, Anatomic Pathology Section, School of Medicine, University of Catania, 95123 Catania, Italy

Department of Biomedical and Biotechnological Sciences, Physiology Section, University of Catania, 95123 Catania, Italy

Department of Biomedical and Biotechnological Sciences, Human Anatomy and Histology Section, School of Medicine, University of Catania, 95123 Catania, Italy

References (100+)

Show source-provided references
1. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus10.1016/0092-8674(90)90601-A ↗
2. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms’ tumor10.1016/0092-8674(90)90690-G ↗
3. Homozygous deletion in Wilms’ tumours of a zinc-finger gene identified by chromosome jumping10.1038/343774a0 ↗
4. Wilms’ tumor suppressor gene WT1: From structure to renal pathophysiologic features10.1681/ASN.V11suppl_2s106 ↗
5. A non-AUG translational initiation event generates novel WT1 isoforms10.1074/jbc.271.15.8646 ↗
6. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties10.1074/jbc.274.33.23456 ↗
7. Alternative splicing and genomic structure of the Wilms’ tumor gene WT110.1073/pnas.88.21.9618 ↗
8. RNA editing in the Wilms’ tumor susceptibility gene, WT110.1101/gad.8.6.720 ↗
9. Expression of the Wilms’ tumor gene (WT1) in human leukemias
10. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth10.1111/j.1349-7006.1999.tb00733.x ↗
11. Overexpression of the Wilms’ tumor gene WT1 in de novo lung cancers10.1002/ijc.10476 ↗
12. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells10.1002/ijc.11721 ↗
13. Overexpression of the Wilms’ tumor gene WT1 in pancreatic ductal adenocarcinoma10.1111/j.1349-7006.2004.tb02490.x ↗
14. Wilms’ tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation
15. Upregulation of Wilms’ tumor gene 1 (WT1) in desmoid tumors10.1002/ijc.20717 ↗
16. Immunohistochemical detection of the Wilms’ tumor gene (WT1) in epithelial ovarian tumors10.1097/00004347-200004000-00010 ↗
17. Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma10.1002/cam4.244 ↗
18. Overexpression of the Wilms’ tumor gene WT1 in primary astrocytic tumors10.1111/j.1349-7006.2004.tb02188.x ↗
19. Wilms’ tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens10.1007/s004320050037 ↗
20. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor10.1097/00043426-200102000-00006 ↗
21. The Wilms’ tumour suppressor WT1 is involved in endothelial cell proliferation and migration: Expression in tumour vessels in vivo10.1038/sj.onc.1211044 ↗
22. The Wilms’ tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression10.1038/ncomms6852 ↗
23. Wilms tumor and the WT1 gene10.1006/excr.2000.5131 ↗
25. Multiple roles for the Wilms’ tumor suppressor, WT1
26. Life, sex, and WT1 isoforms--three amino acids can make all the difference10.1016/S0092-8674(01)00469-X ↗
27. The Wilms’ tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes10.1093/hmg/ddh040 ↗
28. A role for the Wilms’ tumor protein WT1 in organ development10.1152/physiol.00048.2004 ↗
29. Transcriptional regulation by WT1 in development10.1016/j.gde.2005.08.004 ↗
30. The many facets of the Wilms’ tumour gene, WT110.1093/hmg/ddl196 ↗
31. Wagner, K.D., El Maï, M., Ladomery, M., Belali, T., Leccia, N., Michiels, J.F., and Wagner, N. (2019). Altered VEGF splicing isoform balance in tumor endothelium involves activation of splicing factors Srpk1 and Srsf1 by the Wilms’ tumor suppressor Wt1. Cells, 8.10.3390/cells8010041 ↗
32. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing10.1016/j.ccr.2011.10.016 ↗
33. The expression pattern of Wilms’ tumour gene (WT1) product in normal tissues and paediatric renal tumours10.1002/(SICI)1096-9896(199606)179:2<162::AID-PATH545>3.0.CO;2-0 ↗
34. Expression of the Wilms’ tumour gene WT1 in the developing human and in paediatric renal tumours: An immunohistochemical study10.1136/mp.50.3.138 ↗
35. The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors10.1097/01.MP.0000028646.03760.6B ↗
36. Immunohistochemical investigation of WT1 expression in 117 embryonal tumors
37. Immunohistochemical expression of Wilms’ tumor protein (WT1) in developing human epithelial and mesenchymal tissues10.1016/j.acthis.2012.04.006 ↗
38. Immunolocalization of Wilms’ Tumor protein (WT1) in developing human peripheral sympathetic and gastroenteric nervous system10.1016/j.acthis.2013.05.003 ↗
39. Cytoplasmic expression of Wilms’ tumor transcription factor-1 (WT1): A useful immunomarker for young-type fibromatoses and infantile fibrosarcoma10.1016/j.acthis.2014.05.010 ↗
40. Wilms’ tumor protein (WT1) in mammary myofibroblastoma: An immunohistochemical study10.1016/j.acthis.2014.03.001 ↗
41. Oncofetal expression of Wilms’ tumor 1 (WT1) protein in human fetal, adult and neoplastic skeletal muscle tissues10.1016/j.acthis.2015.02.012 ↗
42. Immunohistochemistry as potential diagnostic pitfall in the most common solid tumors of children and adolescents10.1016/j.acthis.2015.03.011 ↗
43. Immunohistochemical detection of WT1 protein in a variety of cancer cells10.1038/modpathol.3800588 ↗
44. WT1 expression in normal and neoplastic cranial and peripheral nerves is independent of grade of malignancy10.3233/CBM-2010-0149 ↗
45. Primary embryonal rhabdomyosarcoma of the prostate in adults: Report of a case and review of the literature10.1177/1066896910395585 ↗
46. A comparative immunohistochemical study of oncofetalcy-toplasmic WT1 expression in human fetal, adult and neoplasticskeletal muscle
47. Wilms’ tumor-1, claudin-1 and ezrin are useful immunohistochemical markers that help to distinguish schwannoma from fibroblastic meningioma10.1007/s12253-011-9456-x ↗
48. The candidate Wilms’ tumour gene is involved in genitourinary development10.1038/346194a0 ↗
49. Molecular-cloning of rat Wilms’ tumor complementary DNA and a study of messenger RNA expression in the urogenital system and the brain
50. The expression of the Wilms’ tumour gene, WT1, in the developing mammalian embryo10.1016/0925-4773(93)90090-K ↗
51. Nuclear localization of the protein encoded by the Wilms’ tumor gene WT1 in embryonic and adult tissues10.1242/dev.119.4.1329 ↗
52. Wilms’ tumor 1 (WT1) protein expression in human developing tissues10.1016/j.acthis.2015.03.009 ↗
53. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation10.1093/hmg/ddh015 ↗
54. WT1 in disease: Shifting the epithelial-mesenchymal balance10.1002/path.2977 ↗
55. WT-1 is required for early kidney development10.1016/0092-8674(93)90515-R ↗
56. Intermediate filament protein nestin is expressed in developing kidney and heart and might be regulated by the Wilms’ tumor suppressor Wt110.1152/ajpregu.00219.2006 ↗
57. The Wilms’ tumor gene Wt1 is required for normal development of the retina10.1093/emboj/21.6.1398 ↗
58. Effect of WT1 gene silencing on the tumorigenicity of human glioblastoma multiforme cells10.3171/2008.11.JNS08368 ↗
59. The NF1 tumor suppressor critically regulates TSC2 and mTOR10.1073/pnas.0503224102 ↗
60. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis10.1242/dev.126.9.1845 ↗
61. Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin10.1038/ng.494 ↗
62. Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms’ tumor transcription factor Wt110.1101/gad.346405 ↗
63. The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis10.1016/j.tig.2012.04.004 ↗
64. Wilms tumor: An update10.1097/PAP.0000000000000017 ↗
65. Wilms’ tumor and other renal tumors of childhood: A selective review from the National Wilms’ Tumor Study Pathology Center10.1016/S0046-8177(83)80003-3 ↗
66. Microdissecting the genetic events in nephrogenic rests and Wilms’ tumor development10.1016/S0002-9440(10)65641-6 ↗
67. Primary renal tumours in the first year of life. A population based review. Virchows
68. The in vitro growth and characterization of the skeletal muscle component of Wilms’ tumor
69. Fetal rhabdomyomatous nephroblastoma-a variant of Wilms’ tumor10.1016/S0046-8177(76)80075-5 ↗
70. Pathology of malignant mesothelioma10.1046/j.1365-2559.1997.5460776.x ↗
71. Differentiation of serosal hyperplasia and neoplasia in biopsies
72. Sarcomatoid mesothelioma: A clinical-pathologic correlation of 326 cases10.1038/modpathol.2009.180 ↗
73. HBME-1, MOC-31, WT1 and calretinin: An assessment of recently described markers for mesothelioma and adenocarcinoma10.1046/j.1365-2559.2000.00770.x ↗
74. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and non pulmonary adenocarcinoma10.1097/00000478-200004000-00016 ↗
75. The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma10.1097/00000478-200308000-00001 ↗
76. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: A comparative study10.1016/j.humpath.2003.11.013 ↗
77. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry10.1111/j.1440-1827.2007.02193.x ↗
78. Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma10.1097/PAI.0b013e318187dd26 ↗
79. Pseudomesotheliomatous carcinoma of the lung. A variant of peripheral lung10.1093/ajcp/65.2.159 ↗
80. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms10.1309/8X4T-35B7-7529-QE7X ↗
81. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids10.1309/QLV6-HH0H-UCTF-WEF6 ↗
82. Wilms’ tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum10.1097/01.pgp.0000092130.10100.88 ↗
83. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: Histogenetic and diagnostic implications10.1097/00000478-200311000-00005 ↗
84. The value of Wilms’ tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma10.1002/cncr.10482 ↗
85. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas10.1309/K84K-005F-TCB8-FV4B ↗
86. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma10.1111/j.1365-2559.2004.01787.x ↗
87. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium10.1097/00004347-200404000-00004 ↗
88. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data10.1097/01.pgp.0000130446.84670.93 ↗
89. Immunohistochemical expression of Wilms’ tumor gene protein in different histologic subtypes of ovarian carcinomas10.5858/2005-129-85-IEOWTG ↗
90. Wilms’ tumor protein 1 (WT1)—Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma10.1016/j.ygyno.2015.12.018 ↗
91. Prognosis of granulosa-theca tumors of the ovary10.1002/1097-0142(196802)21:2<255::AID-CNCR2820210214>3.0.CO;2-5 ↗
92. Ovarian sex cord-stromal tumors with bizarre nuclei: A clinicopathologic analysis of 17 cases10.1097/00004347-198301040-00002 ↗
93. Ovarian granulosa cell tumors with bizarre nuclei: An immunohistochemical analysis with fluorescence in situ hybridization documenting trisomy 12 in the bizarre component [corrected]
94. Sex cord-stromal tumors of the ovary and testis: Their similarities and differences with consideration of selected problems10.1016/S0893-3952(22)04460-X ↗
95. Immunohistochemical expression of inhibin/activin subunits in epithelial and granulosa cell tumours of the ovary10.1002/(SICI)1096-9896(199704)181:4<413::AID-PATH789>3.0.CO;2-U ↗
96. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors10.1016/j.humpath.2004.11.011 ↗
97. Ovarian sex cord-stromal tumors: An immunohistochemical study including a comparison of calretinin and inhibin10.1097/01.MP.0000073133.79591.A1 ↗
98. Expression of CD56 and WT1 in ovarian stroma and ovarian stromal tumors10.1097/PAS.0b013e3181609d59 ↗
99. Diagnostic utility of WT1 immunostaining in ovarian Sertoli cell tumor10.1097/PAS.0b013e3180339961 ↗
100. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors10.1097/PAS.0b013e318188373d ↗